Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

Journal of Acquired Immune Deficiency Syndromes

Volumn 75, Issue 2, 2017, Pages 211-218

  Arribas, José R ^a   Thompson, Melanie ^b   Sax, Paul E ^c   Haas, Bernhard ^d   McDonald, Cheryl ^e   Wohl, David A ^f   Dejesus, Edwin ^g   Clarke, Amanda E ^h   Guo, Susan ⁱ   Wang, Hui ⁱ   Callebaut, Christian ⁱ   Plummer, Andrew ⁱ   Cheng, Andrew ⁱ   Das, Moupali ⁱ   McCallister, Scott ⁱ  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b AIDS Research Consortium of Atlanta   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Department of IT and Telecommunications   (Austria)

^e Tarrant County Infectious Disease Associates   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g ORLANDO IMMUNOLOGY CENTER   (United States)

^h ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

ⁱ GILEAD SCIENCES   (United States)

Author keywords

bone mineral density; HIV; integrase inhibitor; randomized controlled trial; renal safety; tenofovir alafenamide

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALCIUM; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CREATINE KINASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRITION SUPPLEMENT; PARATHYROID HORMONE; PROTEIN; RETINOL BINDING PROTEIN; TRIACYLGLYCEROL; VIRUS RNA; VITAMIN D; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; GS-7340; QUINOLONE DERIVATIVE; TENOFOVIR;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ACUTE PANCREATITIS; ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; BONE DENSITY; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR DISEASE; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FRACTURE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOVOLEMIC SHOCK; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SHOULDER IMPINGEMENT SYNDROME; SIDE EFFECT; SPONTANEOUS ABORTION; STAPHYLOCOCCAL SKIN INFECTION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

ADENINE; ANTI-HIV AGENTS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; COBICISTAT; DOUBLE-BLIND METHOD; EMTRICITABINE; HIV INFECTIONS; HUMANS; MIDDLE AGED; QUINOLONES; TENOFOVIR; TREATMENT OUTCOME; UNITED STATES;

EID: 85014799936     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001350     Document Type: Article

References (27)

1. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52: 3144-3160.
2. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165-1173.
3. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197: 102-108.
4. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-272.
5. Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-780.
6. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385:2606-2615.
7. Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, doubleblind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58-64.
8. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study. Lancet Infect Dis. 2016;16:43-52.
9. Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, phase 3 study. J Acquir Immune Defic Syndr. 2016;71:530-537.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Washington, DC: U. S. Department of Health and Human Services; 2016. Available at: https://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed August 26, 2016.
11. Gänthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016; 316:191-210.
12. AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases, Clinical Microbiology, the National AIDS Plan. Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016). Enferm Infecc Microbiol Clin. 2016;34:439-451.
13. Ministry of Health, National Committee on AIDS-Commissione Nazionale per la lotta contro l'AIDS. Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnosticoclinica delle persone con infezione da HIV-1 [in Italian]. Rome, Italy: Ministero della Salute; 2015. Available at: http://www.salute.gov.it/imgs/C-17-pubblicazioni-2442-allegato.pdf. Accessed April 15, 2016.
14. Danish Society of Infectious Diseases. Antiviral behandling af HIV smittede personer, Odense C, DK. August 2015 [in Danish]. Available at: http://www.infmed.dk/guidelines. Accessed April 15, 2016.
15. Snopková S, Rozsypal H, Aster V, et al. Doporu-cený postup pé-ce o dosp-elé infikované HIV a postexpozi-cní profylaxe infekce HIV [in Czech]. Klin Mikrobiol Infekc Lek. 2016;22:20-38.
16. DAIG j Deutsche AIDS-Gesellschaft e.V. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, Version 6 [in German]. Hamburg, DE: DAIG; 2015. Available at: http://www.daignet. de/site-content/hiv-therapie/leitlinien-1. Accessed April 15, 2016.
17. Smith F, Hammerstorm T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J. 2011; 45:291-300.
18. Segal-Maurer S, Henry K, Benson P, et al. Common adverse drug reactions of elvitegravir, cobicistat, and emtricitabine co-formulated with tenofovir alafenamide or tenofovir disoproxil fumarate. Presented at the 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; September 12-13, 2016; New York, NY. Poster #P19.
19. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61:32-40.
20. Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6:8-14.
21. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781-1784.
22. Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebocontrolled trial. Clin Infect Dis. 2015;61:403-408.
23. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/ emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17: 1011-1020.
24. Mulligan K, Glidden DV, Anderson PL, et al. Decreases in cholesterol in HIV-seronegative men using emtricitabine/tenofovir pre-exposure prophylaxis: lipid results of iPrEx. Presented at the 15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; October 15-17, 2013; Brussels, Belgium. Available at: http://www.intmedpress.com/serveFile.cfm? sUID=bc75b62c-c206-437a-b725-a75baa67f5b2. Accessed September 13, 2016.
25. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-S73.
26. Friis-Møller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23:214-223.
27. Huhn G, Shamblaw D, Baril JG, et al. Atherosclerotic CVD risk profile of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Presented at the 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; September 12-13, 2016; New York, NY. Available at: http://www.natap.org/2016/AGE/AGE-17.htm. Accessed December 16, 2016.